Live Evaluations
Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling
About
Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling
This activity is supported by an educational grant from Castle Biosciences.
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the role of gene expression profiling for the management of skin cancers
Describe how to integrate gene expression profiling for cutaneous melanoma and SCC to inform risk- and appropriate management decisions
Intended Audience
Faculty
Laura Ferris, MD, PhD
Professor and Director of Clinical Trials, Dermatology
University of Pittsburgh
Pittsburgh, PA
Darrell Rigel, MD, MS
Clinical Professor of Dermatology
Director, Melanoma Surveillance Clinic
Mount Sinai Icahn School of Medicine, New York, NY
Adjunct Professor, UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic, Dallas, TX
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: Castle Biosciences, SciBASE
Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics
Speakers’ Bureau or Honoraria: Castle Biosciences
Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.